Mds Informaticki Inzenjering company information, Employees & Contact Information

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS OncLive

(PDF) Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations researchgate.net

How I treat iron overload in adult MDS ScienceDirect.com

How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome Wiley Online Library

MD Anderson Research Highlights: ASH 2024 Special Edition MD Anderson Cancer Center

SF3B1- mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms Nature

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry Taylor & Francis Online

Myelodysplastic Syndrome (MDS): Practice Essentials, Pathophysiology, Etiology Medscape eMedicine

Understanding iron homeostasis in MDS: the role of erythroferrone Frontiers

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) – “2021 update on diagnosis, risk-stratification, and management” Wiley Online Library

Management of patients with lower-risk myelodysplastic syndromes Nature

SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level ScienceDirect.com

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis | Leukemia Nature

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis Nature

Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T Wiley Online Library

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients | Blood Cancer Journal Nature

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms Nature

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis Nature

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms | Blood Cancer Journal Nature

Evolving MDS Treatment Options and the MEDALIST Trial Docwire News

Approaches to the Diagnosis and Risk Stratification of MDS to Guide Precision Therapy ASCO Daily News

COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS Targeted Oncology

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts Nature

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions Bristol Myers Squibb

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis ScienceDirect.com

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis Frontiers

Molecular aberrations in myelodysplastic syndromes - Shah - 2021 - ADVANCES IN CELL AND GENE THERAPY Wiley Online Library

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome–Refractory Cytopenia With Multilineage Dysplasia ScienceDirect.com

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry Taylor & Francis Online

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process Frontiers

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts Nature

ASCO 2023 – Bristol’s Commands data look good for Geron | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome ScienceDirect.com

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage Wiley Online Library

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome Nature

Prevalence and Types of Myelodysplastic Syndromes (MDS) Pharmacy Times

Myelodysplastic Syndrome Treatment & Pharmacologic Management Cancer Therapy Advisor

Potential new therapy for MDS blood cancer Knut och Alice Wallenbergs Stiftelse

Transitioning from ESAs to EMAs in MDS Treatment Targeted Oncology

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa Frontiers

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves OncLive

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients Wiley Online Library

Upfront Therapy for Anemia in Lower-Risk Myelodysplastic Syndromes: Luspatercept for All or for Some? ASCO Daily News

Luspatercept in MDS Promotes Transfusion Independence and Anemia Response Targeted Oncology

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms ScienceDirect.com

Monocytosis May Be a Sign of Trouble for Patients with Myelodysplastic Syndromes MedPage Today

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS CancerNetwork

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes OncLive

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes Medical Professionals Reference

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial The Lancet

FDA Approves First Erythroid Maturation Agent to Treat Anemia in Patients with Myelodysplastic Docwire News

Features and Outcomes in Myelodysplastic Syndrome, Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis Hematology Advisor

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation Frontiers

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML Nature

Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes Hematology Advisor

‘BMS’ Reblozyl to ease blood transfusion burden for MDS-RS patients’ koreabiomed.com

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts Nature

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes Nature

FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes Medical Professionals Reference

FDA Approves Luspatercept for MDS-Associated Anemia OncLive

Diagnostic algorithm for lower-risk myelodysplastic syndromes Nature

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes The New England Journal of Medicine

ASCO: Bristol Myers' $4B plan for Reblozyl takes shape in blood cancer anemia—with one caveat Fierce Pharma

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS Targeted Oncology

Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS Targeted Oncology

FDA Approves Luspatercept as First-Line Anemia Treatment in Patients With Lower-Risk MDS AJMC

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment Nature

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis Frontiers

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts Wiley Online Library

Diagnosed With a Rare Disease, This Woman Found a Way Forward Prevention

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis Wiley Online Library

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod Fierce Pharma

BMS anemia drug Reblozyl arrives in Korea swiftly koreabiomed.com

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1 -mutant myelodysplastic syndromes Nature

(PDF) Perls’ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC) researchgate.net

BMS Korea gets regulatory nods for 2 myelofibrosis treatments koreabiomed.com

(PDF) Megaloblastic Anaemia With Ring Sideroblasts Not Always Mds researchgate.net

(PDF) Causes and Pathophysiology of Acquired Sideroblastic Anemia researchgate.net

(PDF) Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options researchgate.net

Almost 50% of Nifty 50 CEOs, MDs earn over Rs 20 crore a year The Economic Times

Sebi fines NSE, 2 ex-MDs total Rs 1.5 crore for co-lo scam Times of India

Sebi fines NSE Rs 1,100 crore, bans two ex-MDs in brokers’ scam Times of India

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG Diploma in ... Medical Dialogues

15 percent Stipend Hike Announced for MBBS Interns, PG medical, MDS, Super-Speciality Doctors in... Medical Dialogues

MD, MS, Diploma, DNB, MDS Admissions in UP: DGME Releases Time Schedule Medical Dialogues

Leaving bond service midway: Rs 40 lakh penalty set for MD, MS, MDS doctors, Rs 20 lakh for PG diploma in ... Medical Dialogues

Rs 5,7 Mds à Betamax: l'extension du délai réclamée par la STC agréée lexpress.mu